Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which dose of vandetanib works best for thyroid cancer?

NCT ID NCT01496313

Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested two daily doses (150mg vs 300mg) of the drug vandetanib in 81 adults with advanced medullary thyroid cancer that had spread or caused symptoms. The goal was to see which dose better shrinks tumors and how side effects compare. Patients took the drug for up to 24 months, with dose reductions allowed for side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
vandetanib
What this could lead to
If successful, this could help doctors choose the best dose of vandetanib to control advanced medullary thyroid cancer with fewer side effects.
What could go wrong
This is a small, completed Phase 4 study, so results may not apply to all patients. Vandetanib can cause serious side effects like heart problems and diarrhea.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

81 people

The number who actually took part.

Started

Jun 2012

Finished

Jul 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Written consent from Female or male patients aged 18 years and over. Previously confirmed histological diagnosis of unresectable, locally advanced or metastatic, hereditary or sporadic MTC Objective disease progression within the previous 14 months prior to enrolment, and/or * Have one or more symptoms that the Investigator believes to be related to the patient's MTC. * World Health Organisation (WHO) or Eastern Cooperative Oncology Group (ECOG) Performance status 0-2. * Has measurable disease (at least one lesion, not irradiated within 12 weeks of study randomisation, with longest diameter more or equal 10mm (lymph nodes minimum more or equal 15 mm) with CT or MRI). * Lesions must be amenable to accurate and repeat measurement. Exclusion Criteria: * Prior treatment (major surgery, radiation therapy, chemotherapy, or other investigational drugs) received within 28 days before randomization. * Abnormal liver function tests (bilirubin more than 1.5xULRR, and ALT, AST, or ALP more than 2.5xULRR or 5.0xULRR if related to liver metastases). * Significant cardiac conditions or events such as reduced cardiac functions, symptomatic cardiac arrhythmia requiring treatment, congenital long QT syndrome, history of drug-induced QT prolongation, or QTcF correction unmeasurable or more than 450 ms. * Abnormal electrolytes such as potassium, magnesium and calcium, or abnormal organ functions such as decreased creatinine clearance. * For women only - currently pregnant or breast feeding.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Medullary thyroid carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Carcinoma, Medullary familial medullary thyroid carcinoma Neoplasm Metastasis thyroid cancer Thyroid Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Thyroid cancer

Contacts and locations

Locations

  • Investigational Site Number : 1901

    Prague, 15006, Czechia

  • Investigational Site Number : 1903

    Olomouc, 77900, Czechia

  • Investigational Site Number : 5703

    Gliwice, 44-101, Poland

  • Investigational Site Number : 5704

    Warsaw, Masovian Voivodeship, 02-781, Poland

  • Research Site

    Houston, Texas, United States

  • Research Site

    Olomouc, Czechia

  • Research Site

    Prague, Czechia

  • Research Site

    Bangalore Karnataka, India

  • Research Site

    Vellore, India

  • Research Site

    Beersheba, Israel

  • Research Site

    Haifa, Israel

  • Research Site

    Jerusalem, Israel

  • Research Site

    Petah Tikva, Israel

  • Research Site

    Catania, Italy

  • Research Site

    Milan, Italy

  • Research Site

    Palermo, Italy

  • Research Site

    Pisa, Italy

  • Research Site

    Roma, Italy

  • Research Site

    Siena, Italy

  • Research Site

    Torino, Italy

  • Research Site

    Groningen, Netherlands

  • Research Site

    Leiden, Netherlands

  • Research Site

    Gliwice, Poland

  • Research Site

    Warsaw, Poland

  • Research Site

    Zgierz, Poland

  • Research Site

    Saint Petersburg, Russia

  • Research Site

    Cardiff, United Kingdom

  • Research Site

    Greater London, United Kingdom

  • Research Site

    London, United Kingdom

  • Research Site

    Tyne & Wear, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.